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Background: Clinical practice guidelines have been widely developed and disseminated with the aim of improving
healthcare processes and patient outcomes but the uptake of evidence-based practice remains haphazard. There is
a need to develop effective implementation methods to achieve large-scale adoption of proven innovations and
recommended care. Clinical networks are increasingly being viewed as a vehicle through which evidence-based
care can be embedded into healthcare systems using a collegial approach to agree on and implement a range of
strategies within hospitals. In Australia, the provision of evidence-based care for men with prostate cancer has been
identified as a high priority. Clinical audits have shown that fewer than 10% of patients in New South Wales (NSW)
Australia at high risk of recurrence after radical prostatectomy receive guideline recommended radiation treatment
following surgery. This trial will test a clinical network-based intervention to improve uptake of guideline
recommended care for men with high-risk prostate cancer.
Methods/Design: In Phase I, a phased randomised cluster trial will test a multifaceted intervention that harnesses
the NSW Agency for Clinical Innovation (ACI) Urology Clinical Network to increase evidence-based care for men
with high-risk prostate cancer following surgery. The intervention will be introduced in nine NSW hospitals over 10
months using a stepped wedge design. Outcome data (referral to radiation oncology for discussion of adjuvant
radiotherapy in line with guideline recommended care or referral to a clinical trial of adjuvant versus salvage
radiotherapy) will be collected through review of patient medical records. In Phase II, mixed methods will be used
to identify mechanisms of provider and organisational change. Clinicians’ knowledge and attitudes will be assessed
through surveys. Process outcome measures will be assessed through document review. Semi-structured interviews
will be conducted to elucidate mechanisms of change.
Discussion: The study will be one of the first randomised controlled trials to test the effectiveness of clinical
networks to lead changes in clinical practice in hospitals treating patients with high-risk cancer. It will additionally
provide direction regarding implementation strategies that can be effectively employed to encourage widespread
adoption of clinical practice guidelines.
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The evidence-practice gap
The discrepancy between research evidence and clinical
practice is well documented [1], and remains one of the
most persistent problems in providing high-quality
healthcare [2]. Clinical practice guidelines have been ex-
tensively developed as a means to disseminate best prac-
tice and ensure clinical decision-making is informed by
recent, credible research evidence, thereby improving
healthcare processes and outcomes. However, timely and
effective implementation of guidelines into clinical prac-
tice is inconsistent [3], and it remains surprisingly difficult
to make changes across the health system even when
there is compelling evidence [4].
The difficulty in achieving large scale adoption of
proven innovations and recommended care (as well as
discontinuing ineffective or harmful practices) has been
characterised as a ‘translation block’ [5-8].
Effective implementation
Previous research indicates that successful implementa-
tion of evidence-based care depends critically on the ex-
tent to which strategies address prospectively identified
barriers, through theoretical frameworks of behaviour
change [9,10], and promote provider acceptance [3].
Recommendations from clinical guidelines are more
likely to become embedded within practice when they:
are initiated and led by local clinical leaders; are tailored
to the local context; and engage clinicians in the design
of the implementation strategy [1,3,11-13]. Grol [14] ar-
gues that to effectively implement evidence-based prac-
tice, research urgently has to change so that it develops
through collaborations between clinicians, researchers, pa-
tients, policy makers, and quality improvement experts.
Specifically, the growing body of evidence suggests sev-
eral core implementation strategies are effective in bring-
ing about system-wide and sustained change [1,11,15,16]:
1. Clinical champions/leaders supporting change
within their practices and settings;
2. System, structural, and organisational support for
system-wide changes to enable implementation
strategies to be rolled out and scaled up (e.g.,
legislation, resources, mechanisms for communication
and collaboration between health sectors);
3. Ongoing monitoring, evaluation, and feedback of
changes as they are implemented.
Clinical networks—a medium for implementation
In New South Wales (NSW), Australia, a coordinated
program of 30 clinical networks, institutes and task-
forces has been established by the NSW Agency for
Clinical Innovation (ACI), a board-governed statutory
organisation funded by the NSW Ministry of Health.These clinical networks of volunteer health profes-
sionals provide a framework for doctors, nurses, allied
health professionals, managers, and consumers to collab-
orate across regional and service boundaries to drive im-
provements in service delivery and care outcomes
through innovation in clinical practice.
This type of non-mandatory clinical network is increas-
ingly being viewed as a vehicle through which evidence-
based care can be embedded into healthcare systems using
a collegial approach to agree on and implement a range of
strategies within hospitals. They provide ‘bottom up’ views
on the best ways of tackling complex healthcare problems
coupled with the strategic and operational ‘top down’
support necessary to facilitate and champion changes in
practice at the clinical interface [17,18]. There is evi-
dence from ‘before and after’ controlled studies that
when clinical practice guidelines are implemented
through clinical networks there are improvements in
compliance with guideline recommendations and the
quality of care [19,20].
Clinical networks embody, or have the potential to en-
able, the core features of successful implementation
strategies and therefore are a mechanism for health sys-
tem change and increasing the uptake of evidence-based
care for three reasons:
1. Clinical networks contain clinical leaders who can
design and champion change to improve care within
their practices and influence wider culture change
within their healthcare settings.
2. Clinical networks are a ‘ready-made’ organisational
structure through which innovations may be
promulgated and accelerated by clinicians.
3. Clinical networks provide a structure to monitor
and evaluate changes as they are implemented to
answer questions about effectiveness and the success
of implementation strategies.
Prostate cancer clinical practice guidelines—an opportunity
to translate research into effective healthcare practice
Prostate cancer is the most common cancer registered
in Australia and is the second highest cause of cancer
death in males [21]. Radical prostatectomy is the most
frequent procedure for localised prostate cancer, how-
ever following surgery it is estimated that 20% to 50% of
men are at ‘high risk’ of experiencing progression or re-
currence [22-25]. A national strategy to improve prostate
cancer services and thereby improve patients’ quality of
life and survival identified the provision of evidence-
based care for these men as a high priority [26]. Persua-
sive evidence from randomised controlled trials indicates
the need to alter current practice by offering radiother-
apy to men with adverse disease features following
surgery as radiotherapy treatment halves the risk of
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free survival [30]. A Grade B recommendation (denoting
that the Clinical Practice Guideline expert working
group considered that the body of evidence can be
trusted to guide practice in most situations) in the Clin-
ical Practice Guidelines for the Management of Locally
Advanced and Metastatic Prostate Cancer produced by
the Australian Cancer Network [31] recommends that
‘patients with extracapsular extension, seminal vesicle
involvement or positive surgical margins receive post-
operative external beam radiation therapy within four
months of surgery.’ This recommendation is echoed in
the more recently published American Urological Asso-
ciation Guideline, Adjuvant and Salvage Radiotherapy
after Prostatectomy, which states ‘Physicians should offer
adjuvant radiotherapy to patients with adverse patho-
logic findings at prostatectomy (Standard; Evidence
Strength: Grade A)’ [32]. The most recently available
data indicate less than 10% of patients with locally ad-
vanced prostate cancer in NSW Australia receive guide-
line recommended care [33]. Patterns of care for
prostate cancer in NSW generally reflect practice in
other Australian jurisdictions [34,35]. These data are
consistent with that from the United States where less
than 20% of eligible patients receive adjuvant radiother-
apy, indicating substantial room for improvement [36].
Current evidence about strategies to encourage the adop-
tion of clinical practice guidelines is limited [1-3,9,37] and
provides little clear direction about approaches that can
be effectively employed in specific settings.
Aims
The aim of this study is to develop and trial a locally tai-
lored, multifaceted implementation strategy that har-
nesses the NSW Agency for Clinical Innovation (ACI)
Urology Clinical Network to increase evidence-based
care for men with high-risk prostate cancer following
prostatectomy in selected NSW hospitals [31]. Specific-
ally, the aim is to increase referral to radiation oncology
for a discussion about radiotherapy, and the associated
risks and benefits of treatment, to support fully informed
decision making.
An additional aim is to identify reasons why changes
in behaviour and outcomes occurred or did not occur in
study hospitals and why the implementation strategy did
or did not result in increased compliance with guideline
recommended care.
If the intervention is successful we will also assess the
sustainability of increases in referral patterns within the
hospitals through interviews with key stakeholders.
Approach to intervention design
Any reason for resisting new practice is a barrier to
change and the potential importance of such barriers andtheir influence on quality improvement activities has been
highlighted in numerous studies [38-41]. A recent system-
atic review indicates that tailored interventions are more
effective when they are designed to address prospectively
identified local barriers to change [10]. A key component
of our method is to tailor our intervention so that it incor-
porates features that will facilitate changes in provider be-
haviour by addressing local level obstacles.
Intervention elements have been informed by reviews of
the clinical practice change literature [9,11,37,38,42-61],
and refined and tailored to take account of the organisa-
tional context in which providers practice through a
multi-component needs and barriers analysis, including:
iterative workshops with members of the ACI Urology
Clinical Network; a national baseline survey (offered in
web-based and paper form) of all urologist members of
the Urological Society of Australia and New Zealand, the
peak professional body, to explore current knowledge,
attitudes and practice in the wider context (results pub-
lished elsewhere); semi-structured interviews with urology,
radiation oncology, and nursing staff at target hospitals to
explore site specific practice and barriers; consumer feed-
back on what information patients want from their urolo-
gist; and consultation with a cancer policy advisory group
to ensure intervention elements are feasible, scalable and
potentially translatable to other cancers (see Figure 1 for
summary).
Results from these activities indicate that, in priority
order, barriers can be grouped into three main clusters:
1. Clinician: attitudes and beliefs held by individual
clinicians about the validity of the evidence base
supporting the guideline recommendation (54% of
urologists surveyed agreed that the
recommendation is based on a valid interpretation
of the underlying evidence) - notably due to
ongoing clinical trials, which raise doubts as to the
treatment benefit of adjuvant radiotherapy versus
early salvage radiotherapy; concerns about
overtreatment and toxicity/side effects associated
with radiotherapy and lack of familiarity with
current radiotherapy techniques (two thirds of
urologists surveyed agreed that patients may
experience unnecessary discomfort if they follow
the recommendation).
2. Patient: treatment preferences (perceived to be
influenced by interaction with urologists).
3. Hospital system and processes: variation in
urologists’ engagement with the multidisciplinary
team (MDT) of specialist surgeons, medical
oncologists, radiation oncologists, nurses and other
allied health professionals providing specialist cancer
care; and selective presentation of high-risk prostate
cancer cases to the MDT resulting in inconsistent
Figure 1 Approach to intervention design.
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Conceptual model
Intervention components are underpinned by the
PRECEDE-PROCEED theory of behaviour change [62,63]
that relates interpersonal factors and system characteris-
tics into one model to inform change in practice. This the-
ory enables the integration of barriers identified through
our mixed methods needs and barriers analysis into ‘pre-
disposing factors’ (e.g., knowledge and attitudes of the
target group); ‘reinforcing factors’ (e.g., opinions and be-
haviour of peers); and ‘enabling factors’ (e.g., capacity of
the system and hospital processes). This is one of the most
widely used theories to support rigorous trials of the im-
plementation of guidelines [16] and systematic reviews
have shown that trials that intervene to alter these three
factors are the most successful [13]. Figure 2 illustrates
how the identified barriers to change in prostate cancer
care have been grouped into the factors of the PRECEDE-
PROCEED theory. Additionally, Figure 2 illustrates the
intervention components that have been designed to tar-
get each barrier.Intervention components
Physician-focused components
1. Provider education (predisposing factor): The
Urologist Clinical Leader at each hospital will be
supported to facilitate an interactive education
session at a routinely scheduled multidisciplinary
team (MDT) meeting. This session will be
moderated by members of the research team to
ensure fidelity and will last approximately 10 to
15 minutes. Participants will be presented with an
introduction to the study, including a summary of
the evidence underlying the guideline recommendation
through a video presentation to control for
inconsistency across sites. The video includes the
Co-Chair of the ACI Urology Clinical Network, a
peer-identified national urologist opinion leader, and a
consumer who introduce key messages through
discussion of their practice and experience.
2. Dissemination of printed materials (predisposing
factor): In the active implementation phase all
urologists will be given a full copy of the Clinical
Practice Guidelines for the Management of Locally
Figure 2 Conceptual model: adaptation of PRECEDE-PROCEED model of behaviour change.
Brown et al. Implementation Science 2014, 9:64 Page 5 of 11
http://www.implementationscience.com/content/9/1/64Advanced and Metastatic Prostate Cancer and a
summary card that allows quick reference to the
evidence supporting the specific recommendation
that is the focus of the study, together with
information on potential side effects and toxicity.
The reverse of this summary card provides
information on current radiotherapy techniques and
key points to guide impartial discussion with
patients before and after surgery to support fully
informed decision-making. This includes the potential
need for multidisciplinary care and consultation with
a radiation oncologist to obtain information about
what radiotherapy would involve and the likely
benefits and risks of treatment if high-risk features are
found upon histopathological examination of the
prostate specimen.
3. Opinion leaders (reinforcing factor): A key aspect of
the intervention will be the use of Urologist Clinical
Leaders in each hospital, identified by peers as being
educationally influential, to engage the target group.
Clinical Leaders will reinforce key messages,
persuade peers to participate in the study and will
model targeted referral behaviours and promote
practice change [64]. Following the educationsession, Clinical Leaders will provide ongoing peer
support and engage in discussions with colleagues to
seek and provide feedback on practice and any
continuing barriers to change. The Clinical Leaders
are members of the ACI Urology Clinical Network
and were recruited by the Network Co-Chair, an
expert opinion leader who is influential due to his
authority and status amongst his peers [65]. The
introduction of key messages by a national opinion
leader in the video presented at the education session
provides an additional level of peer-to-peer influence.
4. Audit and feedback (reinforcing factor): Following
commencement of the intervention, urologists will
be provided with ongoing feedback reports detailing
the number of patients referred to radiation
oncology, at the individual, hospital and study level,
obtained through data extraction from medical
records. The feedback report will also include
information on the number of patients at high risk
who are discussed at MDT meetings. The initial
feedback report will include baseline data. Feedback
will be provided via email or SMS depending on the
preferred method of communication of each
participant. Aggregated quarterly feedback reports
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Context-focused components
Guideline dissemination and educational components will
address gaps in provider knowledge. However, a number
of reviews indicate that increased knowledge is necessary
but insufficient to change individual or organisational be-
haviour [41]. It is also necessary to enable change by in-
creasing means or reducing barriers [66]. Therefore, in
conjunction with physician-focused components, utilising
the leverage of the ACI Urology Clinical Network to ad-
dress the systems barriers identified through the mixed
methods needs and barriers analysis, context-focused
components will include a new system for automatic case
flagging at MDT meetings (enabling factor). Urologists
practising at the nine target hospitals will be requested to
provide consent for the names of all patients who have
had a histopathological examination of a radical prostatec-
tomy specimen and who have extracapsular extension,
positive surgical margins or seminal vesicle involvement to
be submitted automatically to the hospital urology MDT
meeting for discussion. Pathology providers will provide a
list of all eligible patients to the MDTcoordinator. This will
reduce variation in practice and selective presentation of
cases to the MDT meeting with the intent to promote
more collaborative decision-making and increased referral
to radiation oncology for high-risk patients.
Methods
Phase I: intervention rollout and implementation trial
Hypotheses
Compared with pre-intervention, a larger proportion of
post-operative radical prostatectomy patients who are atFigure 3 Stepped wedge study design: staged rollout of intervention
represent introduction of the intervention over 5 steps. The intervention w
medical records will be reviewed for a period of 12 months following the i
completed until September 2015. *Control-only monitoring not part of thehigh risk of recurrence (have extracapsular extension,
seminal vesicle involvement or positive surgical margins)
treated in hospitals after implementation of the interven-
tion will receive a referral to radiation oncology for con-
sideration of adjuvant radiotherapy or referral to the
RAVES trial [Radiotherapy Adjuvant Vs Early Salvage
(Protocol Number: TROG.08.03); see the ‘RAVES Trial’
subsection for details].
Design
This will be a phased randomised cluster trial with phased
introduction of a clinical network led organisational inter-
vention in nine hospitals over 10 months. The order in
which hospitals will receive the intervention will be deter-
mined randomly using a stepped wedge study design (see
Figure 3). This design, originally developed for community
studies, has more recently been applied to health service
interventions in hospitals [67] and has the following ad-
vantages: provides a control comparison where geographic
controls are not possible; allows all hospitals in the clinical
network with multidisciplinary teams to take part in the
intervention; enables the intervention to be tested within
the parameters of real-world allocation of clinical network
resources with a phased roll out of the hospital-based
intervention; and complies with the Cochrane Effective
Practice and Organisation of Care Group’s consensus
statement about study designs of sufficient quality to be
included in systematic reviews. This study will be con-
ducted and reported in accordance with the CONSORT
statement for the reporting of pragmatic trials [68,69].
The intervention will be rolled out across the nine
hospitals in five steps of two-month blocks from
December 2013 to September 2014. Throughout the
study, hospitals will either be in the active implementationfrom December 2013 to September 2014. The solid shaded blocks
ill be rolled out across the nine hospitals in two-month blocks. Patient
nteractive education session. Therefore data collection will not be
intervention study.
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Eligibility criteria for inclusion are public hospitals: with a
urology multidisciplinary team (MDT) comprising special-
ists, nurses, and allied health professionals; and that are
members of the ACI Urology Clinical Network and have a
urologist who will act as the Clinical Leader for that site.
All urologists who are members of the urology multidis-
ciplinary team at intervention hospitals will be eligible for
inclusion (n ≈ 4 – 10 urologists per hospital).
Outcomes
Primary outcomes are patient referral to radiation oncol-
ogy for discussion of adjuvant radiotherapy in line with
guideline recommended care or referral to the RAVES
trial (see the ‘RAVES Trial’ subsection for details). Sec-
ondary outcomes include: an initial patient consultation
with a radiation oncologist; enrolment in the RAVES
trial; and commencement of radiotherapy.
RAVES Trial – an opportunity to demonstrate shift in
equipoise
RAVES [Radiotherapy Adjuvant Vs Early Salvage (Protocol
Number: TROG.08.03)] is a multi-centre phase III clinical
trial comparing survival and quality of life outcomes for
patients at high-risk post prostatectomy who are rando-
mised to have: i) radiotherapy deferred (salvage radiother-
apy) until their prostate specific antigen (PSA) begins to
rise (common current practice); OR ii) immediate radio-
therapy (adjuvant radiotherapy) after surgery (regarded as
evidence-based standard of care). This is seen as a very
important local trial as, despite international evidence that
adjuvant radiotherapy is effective, this practice has not
been widely adopted due to Urologists’ concerns about
side effects and overtreatment. The aim of the RAVES
trial is to determine whether salvage radiotherapy is as ef-
fective as adjuvant radiotherapy and results in improved
quality of life.
Data collection—data extraction from patients’ medical
records
Outcome data to assess changes in healthcare practice will
be collected through data extraction from urologists’ and
radiotherapy patients’ medical records by independent,
trained research assistants who are blind to the date that
the intervention was commenced at the hospital. Baseline
data will be collected retrospectively for patients undergo-
ing a radical prostatectomy during January 2013 to
November 2013. Pilot testing of the medical record review
tools and processes will allow us to train the research as-
sistants and establish and test data collection procedures.
Information from medical records
Treatment outcomes that will be collected through med-
ical record review for cases with extracapsular extension,seminal vesicle involvement or positive surgical margins
(confirmed by pathology reports) are: referral to radio-
therapy, taken from the surgeon’s notes (including dates
of surgery and referral) or in the case where there was
no referral that radiotherapy was discussed and the rea-
son(s) for not referring to radiotherapy; uptake of radio-
therapy or enrolment into the RAVES trial from the
radiation oncology database; and time between surgery
and commencement of radiotherapy. Individual case re-
cords will be reviewed for a minimum of six months
after initial radical prostatectomy.
Data will be abstracted from medical records at hospi-
tals, cancer centres and urologists’ private consulting
rooms using previously established methods [33].
Hospital level factors will be collected from centrally held
records including specialist cancer centre and size. Patient
level factors will be collected from the medical and hospital
records including: month and year of birth, comorbidities,
stage of cancer, Gleason score, PSA level at diagnosis,
country of birth and private health insurance status.
Remoteness of residence and socio-economic status (SES)
of the cases will be assigned using their postcode of resi-
dence and the ARIA [70] and SEIFA [71], respectively.
Hormone therapy, comorbidities, pre-diagnostic PSA
levels, Gleason score, country of birth, and health insurance
status are potential barriers to referral for radiotherapy.
Study sample
The unit of study will be the participating multidisciplin-
ary teams (MDT). Nine public hospital-based MDTs in
NSW will participate. The hospitals are located in both
metropolitan and regional areas. Approximately four to
ten urologists will be included at each site.
Data analysis
The primary analysis will be conducted at the individual
patient level using a generalized estimating equations
(GEE) approach to account for repeated outcome obser-
vations within clusters (urologists and MDTs). The
dependent variable for this analysis will be referral to a
radiation oncology service for adjuvant radiotherapy or
enrolment into the RAVES trial (versus no referral) for
each prostate cancer case. The exposure variable will be
the intervention status (pre versus post) of the hospital
at the time of the post-prostatectomy consultation.
Other independent variables will be added to the model
if they are shown to be independently associated with
radiotherapy referral and/or their inclusion in the model
changes the linear coefficient of the intervention effect
by more than 20% in absolute value. Analysis to deter-
mine the extent to which changes in urologists’ know-
ledge, attitudes and beliefs (Phase II) mediated any
changes in referral patterns will be assessed by including
clinicians’ change scores in the GEEs.
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Based on estimates from the NSW Central Cancer
Registry and Medicare claims data we estimate that
3,517 NSW men will have a radical prostatectomy in
2013. Approximately 1,618 (46%) of these will be per-
formed in the nine hospitals with urological MDTs
participating in the ACI Urology Clinical Network ac-
cording to linked cancer registry and hospital data for all
NSW men diagnosed with prostate cancer. Assuming no
major change has occurred in this distribution, there will
be 1,348 radical prostatectomies over the 10 months of
this trial. Of these, 20 to 50% or 270 to 671 men will be
at ‘high risk’ [22-25]. The stepped wedge design is rela-
tively insensitive to variations in the intracluster correl-
ation (ICC) as a consequence of its efficient use of
within-cluster and between-cluster information and has
little impact on the study's power. However, based on the
best available information, we estimate that the ICC for
use of radiotherapy will be between 0.09 and 0.15 [72].
The most recently available data indicate 10% of high-
risk men receive radiotherapy after surgery in NSW [33].
With the release of the Australian Cancer Network Clin-
ical Practice Guidelines and the commencement of the
RAVES trial we estimate that at the commencement of
our trial, administration of radiotherapy following
surgery will have increased to 15% to 20% of high-risk pa-
tients. Our stepped wedge study design with nine clusters,
six time intervals (including the pre-intervention control
step) and ICCs of 0.09 to 0.15 will have at least 80% power
to detect an increase in referral to a radiation oncologist
from 15% to 35%, or 20% to 40% if a minimum of 30% of
patients are at high risk, and from 20% to 35% if at least
50% of prostate cancer cases are at high risk.
Staff training and evaluation
Primary and secondary outcomes can be measured reliably
through clinical data collection and this method has been
used previously [33,73,74]. Research assistants conducting
the medical record review will be trained and we will con-
duct a 10% blinded re-review to assess inter-rater reliability.
Phase II: identify mechanisms of provider and
organisational change
Design
‘Before and after’ mixed methods study to measure
knowledge, attitudes, process, and explanatory variables.
Urologists’ knowledge and attitudinal outcomes
Hypotheses
Compared with pre-intervention measures, urologists
post-intervention will have: increased knowledge about
the evidence for appropriate adjuvant radiotherapy for
high-risk prostate cancer patients after radical prostatec-
tomy and the associated risks and benefits of treatment;and more positive attitudes towards the need for referral
to radiation oncology as a means to support fully-
informed patient decision making.
Data collection
A quantitative study of urologists will be conducted
using a questionnaire to assess knowledge, beliefs, social
influences, attitudes and motivation at three time points:
baseline (pre-intervention); six months after the roll-out
of the intervention; and at the end of the study (n ≈ 4 –
10 urologists per hospital). The survey is tailored to the
intervention, uses previously identified domains (know-
ledge, beliefs, motivation, social influences), constructs,
and generic questions to investigate the implementation
of evidence-based practice [48], and is modelled on
questions developed for other clinical conditions [75].
The measures using Likert scales have been developed
through pilot testing and their feasibility and reliability
will be assessed as part of the data collection in accord-
ance with best practice [76]. Questions are consistent with
those used in the baseline nationwide survey of urologists
to enable comparison between groups. These surveys pro-
duce continuous scores for knowledge, beliefs, social influ-
ences, attitudes, and motivation at the clinician level that
will be averaged for each hospital at each time point.
A follow up nationwide survey of urologist members
of the Urological Society of Australia and New Zealand
(USANZ) (n ≈ 370) will be conducted to determine




Was the intervention implemented as intended?
Data collection
The date of commencement of the intervention will be
noted as the day the Urologist Clinical Leader within
each site facilitated the educational intervention session.
Agendas and minutes of subsequent MDT meetings will
be reviewed using a method developed by members of
the investigator team [77] to assess: numbers attending
the meeting; frequency of mentioning the study; discus-
sion of cases flagged by pathology; presentation of med-
ical record review feedback; and changes in hospital
practice as indicators of sustained interest in the inter-
vention and organisational process changes.
Research questions
1. Why did or did not the intervention result in
evidence-based care?
2. Why was or was not the intervention implemented
or sustained in hospitals?
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1. Qualitative semi-structured interviews with Clinical
Leaders at the end of the study to feedback study
results and explore the reasons for them (n = 9).
2. Qualitative semi-structured telephone interviews,
informed by feedback from Clinical Leaders, with
urologists in the nine intervention hospitals at the
end of the study to feedback study results and
further explore the reasons for them (n ≈ 4 – 10
urologists per hospital).Data analysis
Survey data will be analysed using bivariable methods
(means, t-tests and ANOVA for normally distributed
continuous data; medians and non-parametric tests for
non-normally distributed continuous data; and proportions
and chi-squared tests for categorical data).
Semi-structured interview data will be analysed the-
matically using a matrix-based framework to organise
data according to the theoretical framework used for the
intervention design to identify why changes did or did
not happen in the hospitals and why the intervention
did or did not result in improved care.Research governance
The study has been approved by Royal Prince Alfred Re-
search Ethics Committee (ID: X12-0388 & HREC/12/
RPAH/584). Site-specific approval (SSAs) from the re-
search governance office at each of the nine participating
hospitals has been obtained. Site-specific approval from
Cancer Council NSW ethics committee has been granted
to cover data collection, storage and analysis at Cancer
Council NSW.Trial status
The intervention and data collection phase of the study
commenced in December 2013.Discussion
Clinical networks such as those established by the NSW
Agency for Clinical Innovation are increasingly being
viewed as an important strategy for increasing evidence-
based practice in Australia and other countries. This
interest in clinical networks is accompanied by signifi-
cant investment in them but few studies have directly
tested their effectiveness in driving implementation ini-
tiatives. To the authors’ knowledge, this study will be
one of the first randomised controlled trials to test the
effectiveness of clinical networks to lead changes in clin-
ical practice in hospitals treating patients with high-risk
cancer and improve evidence-based care.Limitations
The aim of this study is to target referral patterns of
practising clinicians using the leverage of a clinical net-
work. Intervention components therefore focus on the
attitudinal and systems barriers at the urologist and hos-
pital level. While we have sought consumer input into
the design of provider-focused materials to provide guid-
ance on what information patients want from consult-
ation with their physician, ethics approval for the
current study does not permit direct interaction with pa-
tients being treated by urologists in the study. The re-
search team is developing a proposal for a sub-study
focused on how patients can influence the treatment
they receive, to be conducted at the end of Phase I.
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